Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SPNG on CNBC ? Great !!
Thanks for sharing the info
GLTYA
Germany 0,013 EUR ~ 0,0177 USD
i´m now in. have a great weekend!
thanks for the link. i´m from germany so i don´t need a translator.
what idiots are selling for 0,0099 pre-market?!
buyout? 15 mio. shares in total or per person?
it means, that a Fund called "KK Immobilien Fonds II" wants to buy 880 shares of GNTA against one share of it´s own...
They don´t even get one share of mine under $0,10
received this letter
http://img89.imageshack.us/img89/2499/gentap.jpg
a reverse split doesn´t affect the market cap of the company
not a bad idea
Chart is still OK
http://img113.imageshack.us/img113/8599/90944467.png
on friday we should know who is the "investor" of the 12 mio $.
someone said 3 days after the news.... should be friday.
correct me if i´m wrong
GLTA
thanks for sharing that video sashex001
EMA40 @ 0.0143
first target for today
after that 0.0185 (EMA48)
i´m long because of that reason.
http://stockcharts.com/h-sc/ui?s=GNTA&p=D&yr=0&mn=3&dy=30&id=p27011495620&a=161321038&listNum=0%22
everything is fine
.138
situation now is much better than 2002
completed patient enrollment into AGENDA
http://biz.yahoo.com/e/090408/gnta.ob8-k.html
hospitals and medical-sites informed! I just sent out the news to medicial websites
what scanner?
14 Mio. tradad in Munich | Germany
price 0.009 EUR thats $0.012
maybe insider yesterday After Hours
what was traded after hours yesterday?
that news should bring it up to $0.025 or more
Genta Announces Completion of Patient Enrollment into Global Phase 3 Trial of Genasense® in Advanced Melanoma
Genta Incorporated (OTCBB: GNTA.OB) announced that the Company had completed patient enrollment into AGENDA, a Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. Final accrual totaled 315 subjects.
“Completion of this trial represents a major milestone for our Company,” said Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. “Over the past 10 years, Genta has made a sustained and substantial commitment toward improving health and outcomes for patients with this devastating illness. This timely completion of accrual is a tribute to the hard work of our employees, physician investigators, study coordinators, patients, and families. Their enthusiasm and the extensive prior data that underlay the planning of this trial offers what we believe is the most promising and exciting advance in melanoma therapy after many decades of setbacks. We currently project that the final assessment of progression-free survival (PFS) will be analyzed approximately 6 months after the last patient has been enrolled. If positive, we plan discussions with global regulatory agencies regarding submissions for marketing approval based on this result coupled with our extensive prior data.”
About AGENDA
AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study was designed to confirm certain safety and efficacy results obtained in a prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood.
Analysis of those efficacy outcomes in GM301, which were observed in 274 patients, showed the following results:
Endpoint
Genasense/DTIC
DTIC
Hazard
Ratio
P
Overall response 20.8% 7.2% 0.002
Durable response 10.7% 2.4% 0.007
Progression-free survival, median 3.6 mos.
1.6 mos.
0.58 < 0.0001
Overall survival, median 12.3 mos.
9.9 mos.
0.64 0.0009
A scientific publication that describes overall efficacy and safety results from the prior study (GM301) can be accessed at: http://jco.ascopubs.org/cgi/content/full/24/29/4738. The co-primary endpoints of AGENDA are progression-free survival (PFS) and overall survival.
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
SAFE HARBOR
1. short covering is coming
-> that means usually a rising stock price
in Munich 1,8 Mio. volume
i meant .02 | 2 cents | $0.02 | -end-
smart money is coming in @ 0.01, because we see 0.02 by end of week.